Targeting the body’s cannabinoid receptors provides a “promising targets” for the treatment of suicidal behavior, according to a new study published by Current Psychiatry Reports.
“The current serotonin-based biological model of suicidal behavior (SB) may be too simplistic”, begins the study’s abstract. “There is emerging evidence that other biomarkers and biological systems may be involved in SB pathophysiology. The literature on the endocannabinoid (EC) systems and SB is limited.” The objective of the present article “is to review all available information on the relationship between cannabinoidreceptors (CB1 and CB2 receptors), and SB and/or psychological pain.”
The review “is limited by the small number and heterogeneity of studies identified: (1) an autopsy study describing elevated levels of CB1 receptor activity in the prefrontal cortex and suicide in both depression and alcoholism and (2) studies supporting the involvement of both CB1 and CB2 receptors in the regulation of neuropathic pain and stress-induced analgesia”, states researchers.
They conclude that” cannabinoid receptors, particularly CB1 receptors, may become promising targets for the development of novel therapeutic tools for the treatment of SB.” Marijuana and its cannabinoids are a natural target and activator of the body’s cannabinoid receptors.
The full study can be found by clicking here.